Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) insider Lisa Bright sold 249 shares of the company’s stock in a transaction that occurred on Friday, November 25th. The stock was sold at an average price of $113.60, for a total transaction of $28,286.40. Following the completion of the transaction, the insider now owns 18,209 shares in the company, valued at approximately $2,068,542.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Lisa Bright also recently made the following trade(s):

  • On Monday, October 3rd, Lisa Bright sold 155 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $163.20, for a total transaction of $25,296.00.

Shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) opened at 104.45 on Wednesday. The stock has a 50 day moving average of $122.88 and a 200 day moving average of $145.74. Intercept Pharmaceuticals Inc. has a 12-month low of $89.76 and a 12-month high of $179.61. The company’s market cap is $2.59 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($3.59) earnings per share for the quarter, beating the consensus estimate of ($3.82) by $0.23. The firm earned $4.70 million during the quarter, compared to analyst estimates of $4.77 million. Intercept Pharmaceuticals had a negative net margin of 3,287.95% and a negative return on equity of 66.97%. The business’s quarterly revenue was up 1051.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($2.10) EPS. Equities research analysts predict that Intercept Pharmaceuticals Inc. will post ($15.63) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

ILLEGAL ACTIVITY WARNING: “Intercept Pharmaceuticals Inc. (ICPT) Insider Lisa Bright Sells 249 Shares of Stock” was published by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The legal version of this piece of content can be viewed at http://www.dailypolitical.com/2016/11/30/intercept-pharmaceuticals-inc-icpt-insider-lisa-bright-sells-249-shares-of-stock.html.

Several research firms have recently weighed in on ICPT. Wells Fargo & Co. reissued a “buy” rating on shares of Intercept Pharmaceuticals in a report on Wednesday, September 28th. Robert W. Baird reissued an “outperform” rating and set a $332.00 price objective on shares of Intercept Pharmaceuticals in a report on Thursday, September 22nd. Credit Suisse Group AG reissued a “buy” rating on shares of Intercept Pharmaceuticals in a report on Thursday, September 22nd. Wedbush reissued an “outperform” rating and set a $239.00 price objective on shares of Intercept Pharmaceuticals in a report on Sunday, September 25th. Finally, JMP Securities reissued a “buy” rating on shares of Intercept Pharmaceuticals in a report on Thursday, August 18th. Five analysts have rated the stock with a sell rating, four have given a hold rating and eleven have issued a buy rating to the company. Intercept Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $177.07.

A number of large investors have recently modified their holdings of ICPT. The Manufacturers Life Insurance Company bought a new stake in shares of Intercept Pharmaceuticals during the third quarter valued at approximately $114,000. CENTRAL TRUST Co bought a new stake in shares of Intercept Pharmaceuticals during the second quarter valued at approximately $107,000. KBC Group NV raised its stake in shares of Intercept Pharmaceuticals by 660.2% in the third quarter. KBC Group NV now owns 897 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 779 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Intercept Pharmaceuticals by 67.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 915 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 370 shares during the last quarter. Finally, Legal & General Group Plc raised its stake in shares of Intercept Pharmaceuticals by 4.5% in the second quarter. Legal & General Group Plc now owns 1,196 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 52 shares during the last quarter. 82.45% of the stock is owned by institutional investors.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

5 Day Chart for NASDAQ:ICPT

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.